Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 16/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20254737 | 1.00 | LTA4H (0.63) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL20254739 | 1.00 | LTA4H (0.63) | LTA4HCA12CA1CA2CA9 | |
| SCHEMBL20261108 | 0.82 | LTA4H (0.64) | LTA4H | |
| SCHEMBL20238663 | 0.81 | LTA4H (0.61) | LTA4H | |
| SCHEMBL20238665 | 0.81 | LTA4H (0.61) | LTA4H | |
| SCHEMBL20995304 | 0.78 | LTA4H (1.00) | LTA4H | |
| SCHEMBL20995305 | 0.78 | LTA4H (1.00) | LTA4H | |
| SCHEMBL21026802 | 0.76 | LTA4H (0.80) | LTA4H | |
| SCHEMBL20253468 | 0.76 | LTA4H (0.80) | LTA4H | |
| SCHEMBL20995300 | 0.73 | LTA4H (0.81) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190161437-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161437-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LTA4H 1/4885CA12 3446/4885CA1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.